Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer - PubMed
5 days ago
- #immunotherapy
- #colorectal cancer
- #neoantigens
- Identification of public neoantigens with broad HLA class I coverage for off-the-shelf cancer vaccine development in colorectal cancer.
- Development of a colorectal cancer-specific neoantigen panel integrating TCGA mutation data with HLA class I binding predictions across 68 alleles.
- Evaluation of candidate neoantigens in a Vietnamese CRC cohort (n=67) based on mutation and HLA matching.
- Functional immunogenicity assessed in patient-derived CD8+ T cells using IFN-γ ELISpot assays and single-cell RNA sequencing.
- Panel comprised 73 recurrent nonsynonymous mutations, achieving >90% population coverage in Asian and Caucasian groups.
- 58% of patients in the Vietnamese CRC cohort harbored at least one matched neoantigen.
- Functional validation demonstrated robust CD8+ T-cell responses against TP53_R273H.
- Neoantigen-reactive T cells exhibited cytotoxic effector function and stem-like memory phenotypes.
- TP53_R273H identified as a clinically relevant shared neoantigen in CRC.
- Integrative computational and experimental framework supports translational feasibility of population-tailored neoantigen panels.